



Press Release

SYNLAB International GmbH
Moosacher Straße 88
80809 Munich
Germany

Munich, 28 October 2024

SYNLAB agrees to sell its Spanish business to Eurofins

SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, agreed to sell its Spanish business to Eurofins Scientific (EUFI.PA). The divestment falls in line with SYNLAB's strategy of further optimising its network and focusing on markets that offer attractive strategic perspectives and sustainable development potential for the Group. The transaction is still subject to customary approvals.

"As a result of a careful review of our portfolio and corresponding market developments in the diagnostics sector, we have decided to sell our Spanish operations to Eurofins Scientific," said Mathieu Floreani, CEO of the SYNLAB Group. "We continue to invest in markets with a higher strategic impact for our Group and adapt our laboratory and service footprint accordingly," Mathieu continued. "We are very grateful for the commitment and achievements of our colleagues in Spain and are confident that they will further thrive in their new company environment."

In 2023, the Spanish business contributed approximately €140 million to the Group's revenue. Until the closing of the transaction, which is expected in the first half of 2025, all SYNLAB services in Spain remain in place without any changes.

– end –

For more information:

Media contact: Steffi Susan Kim, FTI Consulting	steffi.kim@fticonsulting.com +49 (0) 171 5565 996
Investor contact: Etienne Ziller, SYNLAB	etienne.ziller@synlab.com +49 (0) 151 6701 3130



About SYNLAB

- SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporates.
- Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
- SYNLAB operates in more than 20 countries across four continents and holds leading positions in most markets. More than 27,000 employees, including over 2,000 medical experts, as well as a large number of other specialists such as biologists, chemists and laboratory technicians, contribute every day to the Group's worldwide success.
- SYNLAB performed around 600 million laboratory tests and achieved revenues of €2.64 billion in 2023.
- More information can be found on www.synlab.com